Theravance Biopharma shares rise 1.95% premarket after being added to S&P Pharmaceuticals Select Industry Index.

Theravance Biopharma, Inc. rose 1.95% in premarket trading, following the news that the company has been added to the S&P Pharmaceuticals Select Industry Index. This inclusion is a significant recognition of Theravance Biopharma's contributions to the pharmaceutical industry, particularly with its focus on developing and commercializing medicines such as YUPELRI for COPD treatment and Ampreloxetine for symptomatic neurogenic orthostatic hypotension.